The −215 region of the CDH1 promoter has also been commonly targeted, with saRNAs designed around this region being shown to successfully upregulate CDH1 in renal carcinoma and breast cancer, and produce beneficial downstream phenotypic effects.23 This evidence concerns the gene CDH1 and breast carcinoma.